Chong Yu to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Chong Yu has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
2.812
-
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019 09; 119:77-86.
Score: 0.410
-
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 08; 117:107-115.
Score: 0.406
-
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896.
Score: 0.393
-
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Lung Cancer. 2018 04; 118:90-96.
Score: 0.368
-
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Cancer Med. 2017 Jul; 6(7):1563-1572.
Score: 0.353
-
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. Oncologist. 2017 09; 22(9):1075-1083.
Score: 0.350
-
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 05; 19(3):e361-e372.
Score: 0.092
-
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018 02; 6(2):107-116.
Score: 0.091
-
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2018 Feb; 126(2):368-374.
Score: 0.090
-
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. J Formos Med Assoc. 2018 Apr; 117(4):326-331.
Score: 0.087
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
Score: 0.086
-
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. Lung Cancer. 2017 02; 104:58-64.
Score: 0.085